CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
Authors
M.M. Hoeper Pausch, C. Grünig, E. Klose, H. Staehler, G. Huscher, D. Pittrow, D. Olsson, K.M. Vizza, C.D. Gall, H. Benjamin, N. Distler, O. Opitz, C. Gibbs, J.S.R. Delcroix, M. Ghofrani, H.A. Rosenkranz, S. Ewert, R. Kaemmerer, H. Lange, T.J. Kabitz, H.-J. Skowasch, D. Skride, A. Jureviciene, E. Paleviciute, E. Miliauskas, S. Claussen, M. Behr, J. Milger, K. Halank, M. Wilkens, H. Wirtz, H. Pfeuffer-Jovic, E. Harbaum, L. Scholtz, W. Dumitrescu, D. Bruch, L. Coghlan, G. Neurohr, C. Tsangaris, I. Gorenflo, M. Scelsi, L. Vonk-Noordegraaf, A. Ulrich, S. Held, M.
Publication date
1 January 2020
Publisher
Abstract
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical presentation of these patients. Using data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, we performed a cluster analysis of 841 patients with IPAH based on age, sex, diffusion capacity of the lung for carbon monoxide (DLCO; <45% vs ≥45% predicted), smoking status, and presence of comorbidities (obesity, hypertension, coronary heart disease, and diabetes mellitus). A hierarchical agglomerative clustering algorithm was performed using Ward's minimum variance method. The clusters were analyzed in terms of baseline characteristics; survival; and response to pulmonary arterial hypertension (PAH) therapy, expressed as changes from baseline to follow-up in functional class, 6-minute walking distance, cardiac biomarkers, and risk. Three clusters were identified: Cluster 1 (n = 106; 12.6%): median age 45 years, 76% females, no comorbidities, mostly never smokers, DLCO ≥45%; Cluster 2 (n = 301; 35.8%): median age 75 years, 98% females, frequent comorbidities, no smoking history, DLCO mostly ≥45%; and Cluster 3 (n = 434; 51.6%): median age 72 years, 72% males, frequent comorbidities, history of smoking, and low DLCO. Patients in Cluster 1 had a better response to PAH treatment than patients in the 2 other clusters. Survival over 5 years was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (unadjusted p < 0.001 for comparison between all groups). The population of patients diagnosed with IPAH is heterogenous. This cluster analysis identified distinct phenotypes, which differed in clinical presentation, response to therapy, and survival. © 2020 The Author
Similar works
Full text
Available Versions
Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lib.uoa.gr:uoadl:3103502
Last time updated on 10/02/2023